These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 35749425)

  • 1. Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19.
    Files DC; Tacke F; O'Sullivan A; Dorr P; Ferguson WG; Powderly WG
    PLoS Pathog; 2022 Jun; 18(6):e1010547. PubMed ID: 35749425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro.
    Okamoto M; Toyama M; Baba M
    Antiviral Res; 2020 Oct; 182():104902. PubMed ID: 32739404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bidirectional Action of Cenicriviroc, a CCR2/CCR5 Antagonist, Results in Alleviation of Pain-Related Behaviors and Potentiation of Opioid Analgesia in Rats With Peripheral Neuropathy.
    Kwiatkowski K; Pawlik K; Ciapała K; Piotrowska A; Makuch W; Mika J
    Front Immunol; 2020; 11():615327. PubMed ID: 33408720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cenicriviroc, a CCR2/CCR5 antagonist, promotes the generation of type 1 regulatory T cells.
    Madan U; Verma B; Awasthi A
    Eur J Immunol; 2024 Jul; 54(7):e2350847. PubMed ID: 38643381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis.
    Lefebvre E; Moyle G; Reshef R; Richman LP; Thompson M; Hong F; Chou HL; Hashiguchi T; Plato C; Poulin D; Richards T; Yoneyama H; Jenkins H; Wolfgang G; Friedman SL
    PLoS One; 2016; 11(6):e0158156. PubMed ID: 27347680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CCR2/CCR5 antagonist cenicriviroc reduces colonic inflammation and fibrosis in experimental colitis.
    Song X; Jiang C; Yu M; Lu C; He X
    J Gastroenterol Hepatol; 2024 Aug; 39(8):1597-1605. PubMed ID: 38744472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cenicriviroc Suppresses and Reverses Steatohepatitis by Regulating Macrophage Infiltration and M2 Polarization in Mice.
    Chen G; Yu Y; Zhu Y; Nagashimada M; Wang Y; Nagata N; Xu L
    Endocrinology; 2024 May; 165(7):. PubMed ID: 38862137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial.
    Pedrosa M; Seyedkazemi S; Francque S; Sanyal A; Rinella M; Charlton M; Loomba R; Ratziu V; Kochuparampil J; Fischer L; Vaidyanathan S; Anstee QM
    Contemp Clin Trials; 2020 Jan; 88():105889. PubMed ID: 31731005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A New Application for Cenicriviroc, a Dual CCR2/CCR5 Antagonist, in the Treatment of Painful Diabetic Neuropathy in a Mouse Model.
    Bober A; Piotrowska A; Pawlik K; Ciapała K; Maciuszek M; Makuch W; Mika J
    Int J Mol Sci; 2024 Jul; 25(13):. PubMed ID: 39000516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis.
    Krenkel O; Puengel T; Govaere O; Abdallah AT; Mossanen JC; Kohlhepp M; Liepelt A; Lefebvre E; Luedde T; Hellerbrand C; Weiskirchen R; Longerich T; Costa IG; Anstee QM; Trautwein C; Tacke F
    Hepatology; 2018 Apr; 67(4):1270-1283. PubMed ID: 28940700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cenicriviroc inhibits trans-endothelial passage of monocytes and is associated with impaired E-selectin expression.
    D'Antoni ML; Mitchell BI; McCurdy S; Byron MM; Ogata-Arakaki D; Chow D; Mehta NN; Boisvert WA; Lefebvre E; Shikuma CM; Ndhlovu LC; Baumer Y
    J Leukoc Biol; 2018 Dec; 104(6):1241-1252. PubMed ID: 30088682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV.
    Kim MB; Giesler KE; Tahirovic YA; Truax VM; Liotta DC; Wilson LJ
    Expert Opin Investig Drugs; 2016 Dec; 25(12):1377-1392. PubMed ID: 27791451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cenicriviroc for the treatment of COVID-19: first interim results of a randomised, placebo-controlled, investigator-initiated, double-blind phase II trial.
    Kurth F; Helbig ET; Lippert LJ; Thibeault C; Barbone G; Eckart MA; Kluge M; Puengel T; Demir M; Röhle R; Keller T; Ruwwe-Glösenkamp C; Witzenrath M; Suttorp N; von Kalle C; Sander LE; Jochum C; Tacke F
    J Glob Antimicrob Resist; 2023 Mar; 32():44-47. PubMed ID: 36572146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates.
    Visseaux B; Charpentier C; Collin G; Bertine M; Peytavin G; Damond F; Matheron S; Lefebvre E; Brun-Vézinet F; Descamps D;
    PLoS One; 2015; 10(8):e0134904. PubMed ID: 26247470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice.
    Guicciardi ME; Trussoni CE; Krishnan A; Bronk SF; Lorenzo Pisarello MJ; O'Hara SP; Splinter PL; Gao Y; Vig P; Revzin A; LaRusso NF; Gores GJ
    J Hepatol; 2018 Sep; 69(3):676-686. PubMed ID: 29802947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cenicriviroc, a dual CCR2 and CCR5 antagonist leads to a reduction in plasma fibrotic biomarkers in persons living with HIV on antiretroviral therapy.
    Bowler S; Siriwardhana C; Mitchell BI; D'Antoni ML; Ogata-Arakaki D; Souza S; Yee R; Gangcuangco LMA; Chow DC; Ndhlovu LC; Shikuma C
    HIV Res Clin Pract; 2019; 20(4-5):123-129. PubMed ID: 32013805
    [No Abstract]   [Full Text] [Related]  

  • 17. Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis.
    Tacke F
    Expert Opin Investig Drugs; 2018 Mar; 27(3):301-311. PubMed ID: 29448843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study.
    Ratziu V; Sanyal A; Harrison SA; Wong VW; Francque S; Goodman Z; Aithal GP; Kowdley KV; Seyedkazemi S; Fischer L; Loomba R; Abdelmalek MF; Tacke F
    Hepatology; 2020 Sep; 72(3):892-905. PubMed ID: 31943293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design.
    Friedman S; Sanyal A; Goodman Z; Lefebvre E; Gottwald M; Fischer L; Ratziu V
    Contemp Clin Trials; 2016 Mar; 47():356-65. PubMed ID: 26944023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the beneficial effects of RS504393, maraviroc and cenicriviroc on neuropathic pain-related symptoms in rodents: behavioral and biochemical analyses.
    Kwiatkowski K; Ciapała K; Rojewska E; Makuch W; Mika J
    Int Immunopharmacol; 2020 Jul; 84():106540. PubMed ID: 32402949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.